Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories


Recode decodes $80m series A
UT Southwestern spinout Recode Therapeutics has completed an oversubscribed $80m series A round featuring Osage University Partners.
Nature's Fynd unearths $80m
The Montana State University-backed edible protein developer has rebranded from Sustainable Bioproducts and received series B funding.
Design unlocks $45m series A
University of Wisconsin-Madison gene medicine developer Design Therapeutics has attracted SR One for its series A round.
Circle Pharma rings up $45m
Circle Pharma, a spinout of UCSF and UC Santa Cruz, has collected series B funding from investors including another UC campus, Berkeley.
Harbour BioMed collects $75m
Humanised antibody-based drug developer Harbour BioMed has now raised $210m altogether following a series B-plus round featuring Zhejiang University Future Capital.
KII responds to APB with investment
Keio Innovation Initative has backed a $74.4m round for the polymer-based battery producer, which is advancing research from Keio's professor Hideaki Horie.
Molekule cleans up with $58m series C
Inventec Appliances Corp has contributed to a round that will enable USF-founded Molekule to further develop and scale its air purification technology.
Tarana starts downloading $60m
Tarana, a broadband services provider advancing research from UC Berkeley, has raised $24m in funding with commitments for an additional $36m.

Other News

OMass compiles $53.9m series A
University of Oxford-founded OMass Therapeutics has extended its series A round to progress a pipeline targeting immunological and genetic disorders.
Sonoma sends for Lyell in $40m series A
Sonoma Biotherapeutics has emerged from stealth with $40m to develop regulatory T-cell therapies for autoimmune and degenerative diseases.
Mammoth evolves with $45m series B
Verily has taken part in an oversubscribed series B round that will fund the UC Berkeley spinout's expansion from diagnostics to gene editing and drug development.
Zinier fields investors for $90m series C
Stanford-StartX's Zinier took its overall funding to $120m in a round that included returning investor Qualcomm Ventures, with the cash to go to international growth and product development.
Jasper grasps $50m
Jasper Therapeutics, based in part on Stanford research, has raised a $15m series A extension on the back of early clinical results from its blood transplant conditioning program.
Deep Genomics dives for $40m
Deep Genomics will use the money to advance drug candidates created through its AI drug development model, based on research by Toronto faculty.

Editor's Picks

Big deal: Oxford PV begins capturing series D
Goldwind, Legal & General and Equinor have all taken part in a series D that achieved a $41m first close and boosted the Oxford spinout’s total equity and debt to more than $118m.
Big deal: Ribon ties together $65m series B
Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.
Big deal: NMD flexes series A muscles
Aarhus University spinout NMD Pharma, which focuses on therapies for neuromuscular conditions, has attracted the support of several corporates for its $47m series A round.
Big deal: Touchstone helps inject $73m into Cell Medica
Touchstone Innovations, which co-founded the cellular immunotherapy developer in 2007, has contributed to another funding round.
test reg